Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.34 |
| ▸ | MDH1 | P40925 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23803972 | 0.87 | NLRP3 (0.40) | MAPTUCHL1 | |
| SCHEMBL26926518 | 0.84 | SMPD1 (0.47) | — | |
| SCHEMBL17429672 | 0.84 | UCHL1 (0.36) | MAPTTDP1L3MBTL1UCHL1TTR | |
| SCHEMBL17386167 | 0.83 | EGFR (0.43) | MAPTALOX5RAB9AUCHL1CREBBP | |
| SCHEMBL5899519 | 0.81 | MAPT (0.50) | MAPTRAB9AUCHL1CA12CA1 | |
| SCHEMBL3633001 | 0.80 | UCHL1 (0.38) | MAPTL3MBTL1ALOX5RAB9AUCHL1 | |
| SCHEMBL17386122 | 0.79 | UCHL1 (0.39) | MAPTTDP1L3MBTL1UCHL1TTR | |
| SCHEMBL17429673 | 0.79 | TDP1 (0.34) | MAPTTDP1L3MBTL1UCHL1TTR | |
| SCHEMBL26688921 | 0.78 | KDM4E (0.40) | MAPTTDP1L3MBTL1UCHL1TTR | |
| SCHEMBL17386366 | 0.77 | UCHL1 (0.36) | MAPTTDP1L3MBTL1UCHL1LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325409-A1 | Fused Heterotetracyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| WO-2024182271-A1 | FUSED HETEROTETRACYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325409-A1 | Fused Heterotetracyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | MAPT 4486/4885TDP1 3903/4885L3MBTL1 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.